Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 6/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29530078 | 1.00 | CYP17A1 (0.46) | CYP17A1ARATRSREBF2CA12 | |
| SCHEMBL15972202 | 0.88 | AR (0.45) | CYP17A1ARATRSREBF2CA12 | |
| SCHEMBL29187149 | 0.87 | AR (0.60) | CYP17A1ARATRSREBF2CA12 | |
| SCHEMBL31166004 | 0.86 | AR (0.43) | CYP17A1ARATRSREBF2CA12 | |
| SCHEMBL31116575 | 0.85 | AR (0.45) | CYP17A1ARATRSREBF2CA12 | |
| SCHEMBL22670384 | 0.85 | AR (0.48) | CYP17A1ARATRSREBF2CA12 | |
| SCHEMBL12852966 | 0.83 | RAF1 (0.51) | CYP17A1CA9MAP4K4SYK | |
| SCHEMBL30293080 | 0.82 | SMARCA2 (0.57) | CYP17A1ATRCA12CA1CA9 | |
| SCHEMBL1501665 | 0.82 | SMARCA2 (0.57) | CYP17A1ARATRCA12CA1 | |
| SCHEMBL16055308 | 0.82 | SMARCA2 (0.57) | CYP17A1ATRCA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MYOKARDIA INC (US) | 2025-09-04 | — | — | US | disclosed |
| CN-118164961-A | 4-Methylsulfonyl substituted piperidine urea compounds for the treatment of Dilated Cardiomyopathy (DCM) | 迈奥卡迪亚公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-111393414-B | 4-Methylsulfonyl substituted piperidine urea compounds for the treatment of Dilated Cardiomyopathy (DCM) | 迈奥卡迪亚公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4234017-A2 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) | MyoKardia, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234017-A2 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) | MyoKardia, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3247707-B1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) | MYOKARDIA INC (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3247707-B1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) | MYOKARDIA INC (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MyoKardia, Inc. | 2022-04-21 | — | — | US | disclosed |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MyoKardia, Inc. | 2022-04-21 | — | — | US | disclosed |
| US-11123337-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | MyoKardia, Inc. (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3247707-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY (DCM) | Myokardia, Inc. (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20160243100-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | MyoKardia, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-20160243100-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | MyoKardia, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-20160243100-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | MyoKardia, Inc. | 2016-08-25 | — | — | US | disclosed |
| WO-2016118774-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY (DCM) | MyoKardia, Inc. (US) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016118774-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY (DCM) | MyoKardia, Inc. (US) | 2016-07-28 | — | — | WO | disclosed |
| EP-1122242-B1 | CYANOPHENYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-20040010037-A1 | Cyanophenyl derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2004-01-15 | — | — | US | disclosed |
| US-6673799-B1 | INHIBITS BINDING TO ANDROGEN RECEPTOR; ANTIANDROGEN | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1122242-A1 | CYANOPHENYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010037-A1 | Cyanophenyl derivative | BPHL, AR, KLK3 | CYP17A1 8/4885AR 2/4885ATR 3090/4885 |
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | CYP17A1 4542/4885AR 3907/4885ATR 3644/4885 |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | CYP17A1 4542/4885AR 3907/4885ATR 3644/4885 |
| US-20160243100-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | TNNI3, UMPS, TNNT2 | CYP17A1 4542/4885AR 3907/4885ATR 3644/4885 |
| US-11123337-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | TNNI3, UMPS, TNNT2 | CYP17A1 4542/4885AR 3907/4885ATR 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.